Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease
Background: Inflammatory rheumatic diseases regularly require the use of disease-modifying antirheumatic drugs (DMARDs). The use of DMARDs in patients with end-stage chronic kidney disease (CKD stage 5D) is particularly challenging due to the lack of systematic studies available for this...
Saved in:
| Main Authors: | Daniel Patschan, Igor Matyukhin, Friedrich Stasche, Oliver Ritter, Susann Patschan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Kidney & Blood Pressure Research |
| Online Access: | https://karger.com/article/doi/10.1159/000544810 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Systemic anticoagulation in progressive chronic kidney disease and atrial fibrillation
by: Henning Hansen-Nootbaar, et al.
Published: (2025-04-01) -
Health Care Quality in CKD Subjects: A Cross-Sectional In-Hospital Evaluation
by: L. Rzayeva, et al.
Published: (2022-01-01) -
Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs
by: A. E. Karateev, et al.
Published: (2019-05-01) -
Metabolomics in spondylarthritis
by: Susann Patschan, et al.
Published: (2025-07-01) -
The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties
by: Garmish O, et al.
Published: (2025-08-01)